The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 3, 2005, Pages 225-227

  Vrijens, Bernard ^a,b,f   Gross, Robert ^c   Urquhart, John ^a,d,e  

^a AARDEX Group   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f AARDEX Ltd   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

AMBULATORY MONITORING; BEHAVIOR; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; ELECTRONIC MONITORING; ELECTRONICS; EXPERIMENTAL DESIGN; LEARNING; LONGITUDINAL STUDY; MEDICAL ETHICS; OBSERVATION; PATIENT COMPLIANCE; PHARMIONICS; POPULATION PHARMACOKINETIC PHARMACODYNAMIC ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT PLANNING; VARIANCE;

ANTI-HIV AGENTS; AUTOMATIC DATA PROCESSING; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; VIRAL LOAD;

EID: 15244355334     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960312.x     Document Type: Conference Paper

References (13)

1. Arnsten, J. H., P. A. Demas, H. Farzadegan, R. W. Grant, M. N. Gourevitch, C. J. Chang, D. Buono, H. Eckholdt, A. A. Howard & E. E. Schoenbaum: Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dix. 2001, 33, 1417-1423.
2. Girard, P., L. B. Sheiner, H. Kastrissios & T. F. Blaschke: Do we need full compliance data for population pharmacokinetic analysis? J. Pharmacokin. Biopharmaceut. 1996, 24, 265-282.
3. Gross, R., W. B. Bilker, H. M. Friedman & B. L. Strom: Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001, 15, 2109-2117.
4. Liu, H., C. E. Golin, L. G. Miller, R. D. Hays, C. K. Beck, S. Sanandaji, J. Christian, T. Maldonado, D. Duran, A. H. Kaplan & N. S. Wenger: A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann. Int. Med. 2001, 134, 968-977.
5. McNabb, J. J., D. P. Nicolau, J. A. Stoner & J. Ross: Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS 2003, 17, 1763-1767.
6. Sheiner, L. B. & T. M. Ludden: Population pharmacokinetics/ pharmacodynamics. Ann. Rev. Pharmacol. Toxicol. 1992, 32, 185-209.
7. Urquhart, J.: The electronic medication event monitor. Clin. Pharmacokin. 1997, 32, 345-356.
8. Urquhart, J.: The odds of the three nons when an aptly prescribed medicine isn't working: noncompliance, nonabsorption, nonresponse. Brit. J. Clin. Pharmacol. 2002, 54, 212-220.
9. Vrijens, B. & E. Goetghebeur: The impact of compliance in PK studies. Statist. Meth. Med. Res. 1999, 8, 247-262.
10. Vrijens, B., S. L. Mayer, R. Rode, R. Bertz, J. Urquhart: Dose-timing information improves the clinical explanatory power of data on patient adherence to antiretroviral drug regimens. Proc. of the twelfth PAGE meeting. Verona (Italy), June 12-13, 2003.
11. Vrijens, B., E. Tousset, R. Rode, R. Bertz, S. L. Mayer: Within-patient variance reduced in an ARV PK study by switching from patient-reported to electronically-compiled dosing times. In: Proc. of the 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003.
12. Vrijens, B. & E. Goetghebeur: Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/ pharmacodynamic population studies. Statist. med. 2004, 23, 531-544.
13. Wagner, G. J.: Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS 2002, 16, 599-608.